🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Cancer or benign tumor

cervical squamous cell carcinoma

A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepi…

🔔 Follow weekly
🧬3254genes / proteins with evidence
💊28drugs and clinical candidates
🧪12+recruiting trials worldwide
✅5phase 3
📈19phase 2
🧬

Understand cervical squamous cell carcinoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.

From the Open Targets disease record ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for cervical squamous cell carcinoma itself.

🤖

AI briefing

Where the science on cervical squamous cell carcinoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens cervical squamous cell carcinoma.

Sign in to ask AI
🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.61
FBXW7 F-box and WD repeat domain containing 7PROTACsmall molecule🧊 AlphaFold structure ↗ 0.57
KMT2C lysine methyltransferase 2CPROTACsmall molecule🧊 AlphaFold structure ↗ 0.56
EP300 EP300 lysine acetyltransferasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.53
KMT2D lysine methyltransferase 2DPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.53
MAPK1 mitogen-activated protein kinase 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.51
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.51
FAT1 FAT atypical cadherin 1PROTACantibody🧊 AlphaFold structure ↗ 0.51
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.51
NOTCH1 notch receptor 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.50
ERBB2 erb-b2 receptor tyrosine kinase 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.49
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.48
RB1 RB transcriptional corepressor 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.44
MAML2 mastermind like transcriptional coactivator 2🧊 AlphaFold structure ↗ 0.44

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to cervical squamous cell carcinoma, by how far it has got
In phase 2 / 3 · 20
CarboplatinPhase 3
CemiplimabProgrammed cell death protein 1 inhibitorPhase 3
CisplatinPhase 3
NimotuzumabEpidermal growth factor receptor erbB1 inhibitorPhase 3
PaclitaxelTubulin inhibitorPhase 3
BevacizumabVascular endothelial growth factor A inhibitorPhase 2
Show all 20
CadonilimabProgrammed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitorPhase 2
CamrelizumabProgrammed cell death protein 1 antagonistPhase 2
CapecitabineThymidylate synthase inhibitorPhase 2
DocetaxelTubulin inhibitorPhase 2
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorPhase 2
ErlotinibEpidermal growth factor receptor erbB1 inhibitorPhase 2
Exatecan MesylatePhase 2
GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 2
IpilimumabCytotoxic T-lymphocyte protein 4 inhibitorPhase 2
LetrozoleCytochrome P450 19A1 inhibitorPhase 2
NivolumabProgrammed cell death protein 1 inhibitorPhase 2
OxaliplatinPhase 2
PembrolizumabProgrammed cell death protein 1 inhibitorPhase 2
RigosertibPhase 2
Early trials · 3
DurvalumabProgrammed cell death 1 ligand 1 inhibitorPhase 1/2
TremelimumabCytotoxic T-lymphocyte protein 4 inhibitorPhase 1/2
Erlotinib HydrochlorideEpidermal growth factor receptor erbB1 inhibitorPhase 1
🧪

Recruiting trials

Worldwide, open to new patients now
Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Ce…NCT07190755 · NA · 📍 RouencDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell CarcinomasNCT07178847 · NA · 📍 AurillacComparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for …NCT07125755 · Phase 3 · 📍 GuangzhouAdebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advance…NCT06510660 · Phase 2 · 📍 Fuzhou3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the…NCT05674396 · Phase 2 · 📍 HoustonA Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · Phase 1 · 📍 BirminghamApplication of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell CarcinomaNCT06755567 · n/a · 📍 GuangzhouRegistry Platform Gastric/Esophageal Cancer (SAPHIR)NCT04290806 · n/a · 📍 Multiple LocationsVoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx CancerNCT04057209 · NA · 📍 ParisAnti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsNCT07360314 · Phase 1 · 📍 New HavenA Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cel…NCT06753747 · Phase 1, Phase 2 · 📍 ChengduNeoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical StudyNCT07437898 · Phase 2 · 📍 Putian Search more trials →
📚

Newest research

Latest papers on PubMed
Early Radiological Response Following Concurrent Chemoradiotherapy and Brachytherapy in Cervical Carcinoma: A Single-Centre Obser…Cureus 2026 · PMID 42928859Challenging diagnostic cases of peripheral ameloblastoma: a case series.J Med Case Rep 2026 · PMID 42928355Bridging the gap: advanced chromatin biotechnologies for circadian epigenomic profiling in head and neck squamous cell carcinoma.Clin Epigenetics 2026 · PMID 42928351Plasmablastic non-Hodgkin's lymphoma: a case report and review of the literature.J Med Case Rep 2026 · PMID 42928269RACIAL DISPARITIES IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: CANCER STEM CELL PATHWAYS AS DRIVERS OF OUTCOME DIFFERENCES.Trans Am Clin Climatol Assoc 2026 · PMID 42927335Sentinel lymph node-guided modification of postoperative radiotherapy in oral tongue squamous cell carcinoma: a retrospective dos…Clin Transl Radiat Oncol 2027 · PMID 42927216Real-world surgical outcomes and prognostic factors in stage III-IVA laryngeal squamous cell carcinoma: a multicenter, retrospect…Int J Clin Oncol 2026 · PMID 42926249Symptom-based vs radiological follow-up in head and neck squamous cell carcinoma: A systematic review.Tumori 2026 · PMID 42924864 Ask a research question in the Hypothesis Lab →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy